Drug Profile
AV 0328
Alternative Names: AV-0328Latest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator Alopexx Vaccine
- Class Antibacterials; Conjugate vaccines; Oligosaccharides; Synthetic vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumococcal infections
- Phase I Meningococcal infections
- Preclinical Alzheimer's disease; Diabetes mellitus
Most Recent Events
- 12 Oct 2023 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Aloplexx
- 06 Jul 2022 Phase-I clinical trials in Meningococcal infections (Prevention) in USA (Parenteral) (Aloplexx pipeline, July 2022)
- 06 Jul 2022 Phase-II clinical trials in Pneumococcal infections (Prevention) (Parenteral) (Aloplexx pipeline, July 2022)